Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11894838 | 0.94 | KDR (0.89) | KDRPDGFRB | |
| SCHEMBL16806545 | 0.94 | KDR (0.88) | KDRPDGFRB | |
| SCHEMBL16806544 | 0.94 | KDR (0.88) | KDRPDGFRB | |
| SCHEMBL16782123 | 0.93 | KDR (1.00) | KDRPDGFRB | |
| SCHEMBL16782148 | 0.93 | KDR (1.00) | KDRPDGFRB | |
| SCHEMBL16782017 | 0.93 | KDR (1.00) | KDRPDGFRB | |
| SCHEMBL16782032 | 0.92 | KDR (1.00) | KDRPDGFRB | |
| SCHEMBL16793356 | 0.91 | KDR (0.85) | KDRPDGFRB | |
| SCHEMBL22367957 | 0.90 | KDR (0.82) | KDRPDGFRB | |
| SCHEMBL22367958 | 0.90 | KDR (0.82) | KDRPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3753935-A1 | SUBSTITUTED DIALKYL(OXIDO)-LAMBDA4-SULFANYLIDENE NICOTINAMIDE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2020-12-23 | — | — | EP | claimed |
| EP-3080105-A1 | SUBSTITUTED DIALKYL(OXIDO)-LAMBDA4-SULFANYLIDENE NICOTINAMIDE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2016-10-19 | — | — | EP | claimed |
| US-9266869-B2 | Substituted dialkyl(oxido)-lambda4-sulfanylidene nicotinamide derivatives as kinase inhibitors | ALLERGAN, INC. (US) | 2016-02-23 | — | — | US | claimed |
| US-20150166521-A1 | SUBSTITUTED DIALKYL(OXIDO)-LAMBDA4-SULFANYLIDENE NICOTINAMIDE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN, INC. | 2015-06-18 | — | — | US | claimed |
| WO-2015089210-A1 | SUBSTITUTED DIALKYL(OXIDO)-Λ4-SULFANYLIDENE NICOTINAMIDE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2015-06-18 | — | — | WO | claimed |
| EP-3753935-A1 | SUBSTITUTED DIALKYL(OXIDO)-LAMBDA4-SULFANYLIDENE NICOTINAMIDE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-3753935-A1 | SUBSTITUTED DIALKYL(OXIDO)-LAMBDA4-SULFANYLIDENE NICOTINAMIDE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-3080105-B1 | SUBSTITUTED DIALKYL(OXIDO)-LAMBDA4-SULFANYLIDENE NICOTINAMIDE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN INC (US) | 2020-09-02 | — | — | EP | disclosed |
| EP-3080105-B1 | SUBSTITUTED DIALKYL(OXIDO)-LAMBDA4-SULFANYLIDENE NICOTINAMIDE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN INC (US) | 2020-09-02 | — | — | EP | disclosed |
| CN-105916850-B | Substituted dialkyl (oxyalkylene) - Λ as kinase inhibitors4-sulfanylidenenicotinamide derivatives | 阿勒根公司 | 2020-03-20 | — | — | CN | disclosed |
| EP-3080105-A1 | SUBSTITUTED DIALKYL(OXIDO)-LAMBDA4-SULFANYLIDENE NICOTINAMIDE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2016-10-19 | — | — | EP | disclosed |
| US-9266869-B2 | Substituted dialkyl(oxido)-lambda4-sulfanylidene nicotinamide derivatives as kinase inhibitors | ALLERGAN, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20150166521-A1 | SUBSTITUTED DIALKYL(OXIDO)-LAMBDA4-SULFANYLIDENE NICOTINAMIDE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN, INC. | 2015-06-18 | — | — | US | disclosed |
| WO-2015089210-A1 | SUBSTITUTED DIALKYL(OXIDO)-Λ4-SULFANYLIDENE NICOTINAMIDE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| US-20150166521-A1 | SUBSTITUTED DIALKYL(OXIDO)-LAMBDA4-SULFANYLIDENE NICOTINAMIDE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN, INC. | 2015-06-18 | — | — | US | disclosed |
| US-20150166521-A1 | SUBSTITUTED DIALKYL(OXIDO)-LAMBDA4-SULFANYLIDENE NICOTINAMIDE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN, INC. | 2015-06-18 | — | — | US | disclosed |
| WO-2015089210-A1 | SUBSTITUTED DIALKYL(OXIDO)-Λ4-SULFANYLIDENE NICOTINAMIDE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166521-A1 | SUBSTITUTED DIALKYL(OXIDO)-LAMBDA4-SULFANYLIDENE NICOTINAMIDE DERIVATIVES AS KINASE INHIBITORS | NADK, MAP4K1, MAP4K2 | KDR 283/4885PDGFRB 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.